Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Pharmacokinetics and Pharmacodynamics

Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers

Eunice Yuen, Robert Bell, Maria Posada, Christophe Massard, Jordi Rodon, Claire Smith, Katharine Thorn, JT Diener, Demetrio Ortega, Jeffrey Suico and Karim Benhadji
Eunice Yuen
1Eli Lilly & Co., Windlesham, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Bell
2Eli Lilly & Co., Indianapolis, IN;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Posada
2Eli Lilly & Co., Indianapolis, IN;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Massard
3Institut Gustave Roussy Cancer Campus, Villejuif Cedex, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordi Rodon
4Vall d´Hebron University Hospital and Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Smith
1Eli Lilly & Co., Windlesham, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katharine Thorn
1Eli Lilly & Co., Windlesham, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JT Diener
2Eli Lilly & Co., Indianapolis, IN;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Demetrio Ortega
2Eli Lilly & Co., Indianapolis, IN;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Suico
2Eli Lilly & Co., Indianapolis, IN;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karim Benhadji
2Eli Lilly & Co., Indianapolis, IN;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-17-B083 Published January 2018
  • Article
  • Figures & Data
  • Info & Metrics
Loading
Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 26-30, 2017; Philadelphia, PA

Abstract

Background: LY3039478 is an oral Notch inhibitor that prevents release of the Notch Intracellular Domain (NICD) by inhibiting proteolytic activity of the gamma (γ)-secretase complex. LY3039478 also inhibits production of plasma amyloid-beta (Aβ), which can be used as a biomarker to determine pharmacodynamic (PD) effects of LY3039478. Covariates affecting the pharmacokinetics (PK) of LY3039478, and also PK-PD relationships, are explored in the current analysis. The analysis included PK and PD data from advanced cancer patients from the first human dose trial and healthy volunteers (HV) from the single ascending dose and pilot relative bioavailability trial. Methods: A summary of the study design elements can be found in Table 1. Population PK and PK/PD models were developed using non-linear mixed effects approaches using NONMEM Version 7.3. A sequential modelling approach was used.

Study ParametersFirst human dose
(NCT01695005)
Single ascending dose and pilot relative bioavailability
(NCT02659865)
PopulationPatients with advanced cancerHealthy volunteers
Dose2.5 to 100 mg thrice weekly (TIW) in dose escalation part; 50 or 75mg TIW in cohort expansion partPart 1: single doses of 25, 50 and 75mg
Part 2: single 50 mg doses in 2 period crossover study
FormulationDrug in capsule (DiC)Part 1: DiC; Part 2: DiC and formulated capsule (fC)
Sample collectionDose escalation patients: Intensive plasma samples up to 30 hours (after 1st and 10th dose); urine samples up to 10 hours (1st dose only)
Cohort expansion patients:
Sparse plasma samples up to 8 hours (1st dose only)
Intensive plasma and urine samples up to 48 hours in both parts
Table 1.

Study Design Elements of the First Human Dose and Healthy Volunteer Trials

Results: The population PK/PD model was developed using data collected from 102 patients and 34 HVs with age range 18 to 82 years and weight between 41 to 140 kg. A 3-compartment PK model with first-order absorption and lag time, plus a urine compartment, best described the LY3039478 disposition. LY3039478 was rapidly absorbed with peak concentrations occurring within 1 to 2 hours. Renal clearance contributed to approximately 20% of the apparent plasma clearance. Formulation and population effects, weight, hematocrit, and glomerular filtration rate affected the disposition of LY3039478. Precursor-dependent indirect response models were used to describe the PK/PD relationships for Aβ inhibition. The PK/PD model identified a maximal plasma Aβ inhibition of close to 100%, and 50% of maximal effects occurred at low LY3039478 concentrations. Patients with advanced cancer appeared to have higher plasma Aβ at baseline and slower loss of response than HVs. Conclusion: When given similar doses of LY3039478, healthy volunteers had higher apparent plasma clearances and therefore lower exposures than patients with advanced cancer. Weight, hematocrit, and glomerular filtration rate were significant covariates affecting the disposition of LY3039478. Patients with advanced cancer appeared to have higher plasma Aβ at baseline and longer sustained response to LY3039478 compared to healthy volunteers.

Citation Format: Eunice Yuen, Robert Bell, Maria Posada, Christophe Massard, Jordi Rodon, Claire Smith, Katharine Thorn, JT Diener, Demetrio Ortega, Jeffrey Suico, Karim Benhadji. Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B083.

  • ©2018 American Association for Cancer Research.
Previous
Back to top
Molecular Cancer Therapeutics: 17 (1 Supplement)
January 2018
Volume 17, Issue 1 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers
Eunice Yuen, Robert Bell, Maria Posada, Christophe Massard, Jordi Rodon, Claire Smith, Katharine Thorn, JT Diener, Demetrio Ortega, Jeffrey Suico and Karim Benhadji
Mol Cancer Ther January 1 2018 (17) (1 Supplement) B083; DOI: 10.1158/1535-7163.TARG-17-B083

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers
Eunice Yuen, Robert Bell, Maria Posada, Christophe Massard, Jordi Rodon, Claire Smith, Katharine Thorn, JT Diener, Demetrio Ortega, Jeffrey Suico and Karim Benhadji
Mol Cancer Ther January 1 2018 (17) (1 Supplement) B083; DOI: 10.1158/1535-7163.TARG-17-B083
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Pharmacokinetics and Pharmacodynamics

  • Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors
  • Abstract C009: Clinical pharmacokinetic and pharmacodynamic analyses support biological effectivity of the PARP inhibitor olaparib as radiosensitizer at low doses
  • Abstract B082: Evaluation of the effects of an oral Notch inhibitor, LY3039478, on QT interval, and absolute and pilot relative bioavailability studies conducted in healthy subjects
Show more Pharmacokinetics and Pharmacodynamics

Pharmacokinetics and Pharmacodynamics: Poster Presentations - Proffered Abstracts

  • Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors
  • Abstract C009: Clinical pharmacokinetic and pharmacodynamic analyses support biological effectivity of the PARP inhibitor olaparib as radiosensitizer at low doses
  • Abstract B082: Evaluation of the effects of an oral Notch inhibitor, LY3039478, on QT interval, and absolute and pilot relative bioavailability studies conducted in healthy subjects
Show more Pharmacokinetics and Pharmacodynamics: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement